Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MERCK & CO., INC.

(MRK)
  Report
Real-time Estimate Cboe BZX  -  04:32:22 2023-01-30 pm EST
106.12 USD   +0.70%
12:25pAstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lung Cancer
MT
11:36aDaiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment
AN
09:24aMerck - FDA Approves KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB, II, or IIIA Non-Small Cell Lung Cancer
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck Names Robert Davis Board Chairman

10/27/2022 | 04:30am EST


ę MT Newswires 2022
All news about MERCK & CO., INC.
12:25pAstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lun..
MT
11:36aDaiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment
AN
09:24aMerck - FDA Approves KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Pl..
AQ
08:01aBerenberg Bank Adjusts Merck & Company Price Target to $125 From $115, Maintains Buy Ra..
MT
01/27Merck Says Keytruda Approved by FDA as Adjuvant Treatment for Non-Small Cell Lung Cance..
MT
01/27FDA Approves KEYTRUDA« (pembrolizumab) as Adjuvant Treatment Following Surgical Resecti..
BU
01/27Merck Announces the U.S. Food and Drug Administration has Approved KEYTRUDA
CI
01/26Merck & Co.'s Animal Health Unit Wins US FDA Nod for Expanded Use of Flea Drug for Dogs
MT
01/26Merck Animal Health Division Says US FDA Approves Expanded Indication of Bravecto Chews..
MT
01/26Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (flu..
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 59 128 M - -
Net income 2022 14 827 M - -
Net Debt 2022 17 475 M - -
P/E ratio 2022 18,0x
Yield 2022 2,65%
Capitalization 267 B 267 B -
EV / Sales 2022 4,81x
EV / Sales 2023 4,75x
Nbr of Employees 67 500
Free-Float 70,8%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 105,38 $
Average target price 116,78 $
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Robert M. Davis Chairman & chief executive officer
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Thomas Henry Glocer Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-5.02%267 180
JOHNSON & JOHNSON-4.77%439 835
ELI LILLY AND COMPANY-6.49%325 056
NOVO NORDISK A/S1.06%312 363
ROCHE HOLDING AG-0.40%277 685
ABBVIE INC.-9.49%258 606